Moderna delivers Canada’s first locally manufactured mRNA vaccines

All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec

Moderna announced the delivery of the first mRNA vaccines fully manufactured in Canada to provinces and territories across the country. This milestone marks a significant step forward in strengthening Canada’s domestic vaccine production capacity and advancing national health security.

“The delivery of the first made-in-Canada mRNA vaccines to provinces and territories across the country marks a major milestone in our partnership with Canada,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This is not just about local manufacturing, it is about scientific leadership, national health security, and ensuring Canadians have timely access to the latest mRNA medicines. We are proud to stand alongside Canada in advancing innovation, driving economic growth, and investing in a resilient future for public health.”

All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec. Fill-and-finish of the new single-use pre-filled syringes is completed by Novocol Pharma in Cambridge, Ontario.

Moderna’s updated COVID-19 vaccine targeting the LP.8.1 variant was approved by Health Canada on August 21, 2025, and has also been authorized by regulators in the United States, Europe, Japan, Switzerland, and several other countries. Additional regulatory submissions are under review globally in preparation for the 2025–2026 respiratory virus season.